Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy - Takeaways - MDSpire

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy

  • By

  • Yao Qiu

  • Xincai Zhao

  • Juan Chen

  • Manman Zhang

  • Yonggang Wang

  • Cheng Guo

  • Jianping Zhang

  • Rong Xu

  • May 29, 2026

Share

  • 1

    In a study of 297 cancer patients, 38.05% experienced immune-related adverse events (irAEs) during combination therapy with immune checkpoint inhibitors.

  • 2

    The most common irAEs were endocrine (12.12%), gastrointestinal (8.75%), and dermatological (6.73%) toxicities, with most occurring within the first 4 treatment cycles.

  • 3

    Corticosteroid use was identified as a protective factor against irAEs, while age ≥65 years was associated with a lower risk of developing these adverse events.

  • 4

    For endocrine irAEs (EirAEs), combination with targeted therapy and higher baseline TSH levels were significant risk factors, with corticosteroids again providing protection.

  • 5

    The findings highlight the need for risk-stratified monitoring and early intervention in patients undergoing ICI combination therapy, warranting further multicenter studies.

Original Source(s)

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy

  • by Yao Qiu, Xincai Zhao, Juan Chen, Manman Zhang, Yonggang Wang, Cheng Guo, Jianping Zhang, Rong Xu

  • May 29, 2026

Related Content

Why We Made a Mobile Digital Pathology Lab

Todd R. Minnigh and his team created ScanVan to address a problem with rare cancer diagnosis that had a particularly personal significance

Could One Test Replace Multiple Leukemia Assays?

Researchers assess whether long-read transcriptome sequencing can streamline B-ALL diagnostics

  • May 29, 2026

  • 3 min
Preclinical Study in Mice Addresses a Question: Should RAS Inhibitors Be Given Preemptively?

With recent data that RAS inhibition can improve survival in metastatic pancreatic cancer, the optimization of these agents has become a research priority. Minh Than, MD, PhD, a clinical and research ...